Bibliography of all studies in evidenceFinder

Last updated August 5, 2019
Ozempic® Phase 3 Studies


3. Aroda V, et al. Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial. Lancet Diabetes Endocrinol. 2017 Link to Access the Full Text


Health Economics and Outcomes Research for Ozempic®


**Victoza® Phase 3 Studies**


Health Economics and Outcomes Research for Victoza®


2. Chitnis A, et al. Real-World Clinical Effectiveness of Liraglutide in Individuals 65 Years and Older with Type 2 Diabetes in the United. *J Diabetes Metab* 5:403. [Link To Access the Full Text]


Xultophy® 100/3.6 mg Phase 3 Studies


5. Philis-Tsimikas A, et al. Superior Efficacy of Insulin Degludec/Liraglutide versus Insulin Glargine U100 as Add-on to Sodium-Glucose Co-Transporter-2 Inhibitor Therapy: a Randomized Clinical Trial in Patients with Uncontrolled Type 2 Diabetes. *Diabetes Obes Metab.* 2019. [Link to Access the Full Text]


Health Economics and Outcomes Research for Xultophy® 100/3.6


Tresiba® Phase 3 Studies


21.  Warren ML, et al. Insulin Degludec 200 Units/mL Is Associated With Lower Injection Frequency and Improved Patient-Reported Outcomes Compared With Insulin Glargine 100 Units/mL in Patients With Type 2 Diabetes Requiring High-Dose Insulin. *Clin Diabetes.* 2017;35(2):90-95. [Link to Access the Full Text]


**Health Economics and Outcomes Research for Tresiba®**


4.  Tibaldi J, et al. A comparative effectiveness study of degludec and insulin glargine 300U/mL in insulin-naïve patients with type 2 diabetes. *Diabetes, Obesity and Metabolism.* 2018;0(ja) [Link to Access the Full Text]
**Saxenda® Phase 3 Studies**


**Health Economics and Outcomes Research for Saxenda®**


2. Kolotkin RL, et al. Improvements in health-related quality of life over 3 years with liraglutide 3.0 mg compared with placebo in participants with overweight or obesity. *Clin Obes.* 2018;8(1):1-10. [Link to Access the Full Text](#)